alexa Cellular, Molecular and Therapeutic Advances in Type 2

Journal of Clinical Diabetes & Practice
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Cellular, Molecular and Therapeutic Advances in Type 2 Diabetes Mellitus

Pravin D. Potdar* and Mayuri B. Chaudhari

Department of Molecular Medicine and Biology, Jaslok Hospital and Research Center, 15 Dr. G. Deshmukh Marg, Mumbai - 400 026, Maharashtra, India

Corresponding Author:
Pravin D. Potdar
Head of Department, Department of Molecular Medicine and Biology
Jaslok Hospital and Research Center
15 Dr. G. Deshmukh Marg, Mumbai - 400 026, Maharashtra, India
Tel: +91-9820833530
E-mail: [email protected]

Received Date: January 06, 2016 Accepted Date: February 1, 2016 Published Date: February 10, 2016

Citation:Potdar PD, Chaudhari MB (2016) Cellular, Molecular and Therapeutic Advances in Type 2 Diabetes Mellitus. J Clin Diabetes Pract 1:104. doi:10.4172/JCDP.1000104

Copyright: © 2016 Potdar PD et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Type 2 Diabetes Mellitus (T2DM) is an ancient disease, discussed 3500 years ago in literature. Vast population worldwide is suffering from this disease and yet it is found to be untreatable. As per WHO statistics 2012, the number of deaths in the world due to T2DM almost reached to 1.5 million. The number of people suffering from T2DM in India is expected to rise from 40.9 million in 2007 to 69.9 million in 2025 due to change in their life style. Of the two types of DM- Type 1 and Type 2, the latter is most common, affecting 80% of DM patients. Modern lifestyle and food habits have been responsible for tremendous rise in the number of patients all over the world. Even though, the symptoms of T2DM are seen in the later stages of life, the onset of the disease occurs quite early. Insulin resistance and β cell dysfunction are the main causative abnormalities. Several mutations in the genes important for glucose homeostasis and β cell development have been related to progress of hyperglycemia, while this progress is related to various metabolic syndromes arising in the patients’ body. Thus, forming a vicious circle of the causes and effects of hyperglycemia interlinked together forming the whole picture of T2DM in the patient. This review discusses these causes and effects at the molecular and cellular levels. The current therapy practices use of oral therapeutic drugs, which controls hyperglycemia and related complications but fails to cure the disease permanently. Hence, stem cell therapy has drawn interest of the researchers in recent times, which seems to be a promising source of remedy for this notorious disease. This review will provide a better understanding of T2DM and associated complications, recent advances in the therapy and the molecular and cellular insights of the disease to the students, clinicians, endocrinologists and diabetologists.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version